Developing a fever after an intravenous stem cell infusion can understandably raise concerns about the quality or safety of the cells. Patients may wonder whether the cells were contaminated, damaged during transportation, or poorly manufactured.

A temporary fever after mesenchymal stromal cell infusion does not, by itself, indicate that the cells are low quality. Fever is a recognized short-term reaction reported across clinical studies of intravenous MSC therapy, including studies specifically involving Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs). Large reviews of clinical research have consistently identified transient fever as one of the more common treatment-related reactions following intravenous MSC administration.

However, this does not mean every fever should automatically be considered a normal response. Persistent, high, or worsening fever still requires appropriate medical assessment because infection, an infusion reaction, or an unrelated illness may produce similar symptoms.

Why Can Fever Occur After a Stem Cell IV Infusion?

Intravenous MSC therapy introduces living cells into the circulation, where they interact with the recipient’s immune system and biological environment. This interaction can temporarily influence inflammatory signaling and may result in symptoms such as mild fever, chills, headache, fatigue, or a general feeling of being unwell in some patients.

The exact mechanism behind post-infusion fever is not completely defined and may differ between patients and cellular products. MSCs are known to communicate with immune cells through cytokines, growth factors, extracellular vesicles, and other signaling molecules. A temporary systemic response can occur during or shortly after this interaction.

Importantly, fever has been observed in controlled MSC research without a corresponding increase in infection. Systematic reviews evaluating thousands of patients receiving intravascular MSCs found fever more frequently among MSC recipients, while infection was not increased compared with control groups.

This distinction is important because it shows that fever can occur even when the cellular product has been produced and administered under controlled research conditions.

Does Fever Mean the Stem Cells Were Contaminated?

Not necessarily. Fever alone cannot determine whether a stem cell product was contaminated.

Contamination is a serious manufacturing concern, which is why clinical-grade cellular products undergo microbiological quality testing before release. Depending on the product and manufacturing protocol, testing may include sterility assessment for bacterial and fungal contamination, mycoplasma testing, endotoxin testing, cell identity, viability, and other release criteria.

FDA guidance for human cellular therapies specifically identifies sterility, mycoplasma, endotoxin, viability, identity, purity, and potency among important product quality considerations. These tests are more meaningful indicators of manufacturing quality than whether an individual patient develops a fever after treatment.

At the same time, a fever should not be dismissed simply because fever is a known treatment-related reaction. If there is concern about infection or contamination, the patient’s symptoms, timing, temperature, physical examination, laboratory findings, and the quality documentation for the cellular product may all need to be considered.

Can Endotoxin Cause Fever?

Endotoxin is one reason cellular products are tested before administration.

Endotoxins are components of certain bacterial cell walls that can trigger strong inflammatory responses in humans. A product can potentially contain endotoxin even when living bacteria are not detected, which is why endotoxin testing is separate from standard sterility testing.

Fever is one possible manifestation of excessive exposure to bacterial endotoxin, but developing a fever after treatment does not prove endotoxin contamination occurred.

Proper quality control therefore evaluates the product before treatment rather than trying to determine product quality based on the patient’s symptoms afterward. Published guidance and clinical-grade MSC manufacturing literature consistently emphasize microbiological testing, mycoplasma assessment, endotoxin testing, cell characterization, and viability as parts of cellular product quality control.

Does Fever Mean the Stem Cells Are Working?

No. Fever should not be interpreted as evidence that stem cell treatment is working. A common misconception in regenerative medicine is that having a stronger reaction means the cells are more active or that the body is responding better to treatment. Current evidence does not support using fever as a marker of therapeutic effectiveness.

Similarly, a patient who does not develop fever should not assume that the cells were ineffective. Clinical response should be evaluated based on appropriate outcomes for the condition being treated, such as pain, physical function, mobility, neurological function, laboratory measures, or other clinically relevant assessments over time. Side effects and treatment effectiveness are separate questions.

Does Fever Mean the Stem Cells Are Being Rejected?

A mild fever alone does not demonstrate immune rejection. UC-MSC therapy differs substantially from organ transplantation and hematopoietic stem cell transplantation. MSCs are generally considered to have relatively low immunogenicity and are not intended to permanently replace the patient’s immune system or remain permanently engrafted.

However, MSCs should not be described as completely invisible to the immune system. The recipient can interact immunologically with donor-derived cells, and researchers continue to study how these interactions may differ with repeated treatment and different cell products.

A temporary fever is therefore better understood as a possible infusion-related or treatment-related reaction rather than proof that the body is rejecting the cells.

When Is Fever After Stem Cell IV Therapy More Concerning?

The severity and pattern of fever matter. A mild, temporary temperature increase occurring relatively soon after an infusion may be consistent with a known short-term treatment reaction. In contrast, fever that is high, progressively worsening, persistent, or accompanied by significant systemic symptoms should be assessed medically.

Symptoms such as shaking chills, difficulty breathing, chest discomfort, confusion, fainting, persistent vomiting, significant weakness, widespread rash, facial or throat swelling, or changes in blood pressure or oxygen saturation should not simply be labelled a normal stem cell reaction.

Similarly, fever developing several days after treatment may have an unrelated cause such as a respiratory, gastrointestinal, urinary, or other infection. The safest approach is to consider the whole clinical picture rather than assuming that every post-treatment symptom originates from the stem cells.

What Actually Determines Stem Cell Product Quality?

The quality of an MSC product is determined before administration through the manufacturing and quality control process, not by whether the patient experiences fever afterward. Clinical-grade manufacturing considers multiple characteristics together.

Cell identity should be confirmed. Viability should be assessed. Sterility, mycoplasma, and endotoxin need appropriate testing. Manufacturing consistency, passage, storage, transportation, and handling conditions may also influence the final product.

Current manufacturing literature emphasizes that no single laboratory measurement can establish complete product quality. A preparation with very high viability, for example, still needs to meet appropriate identity and microbiological standards

This is why patients evaluating stem cell treatment should focus on manufacturing transparency and documented quality control rather than interpreting a temporary fever as evidence for or against the quality of the cells.

What Is the Most Important Takeaway?

A temporary fever after intravenous UC-MSC therapy can occur and has been repeatedly reported in clinical research. On its own, it does not mean the cells were contaminated, poorly manufactured, rejected by the body, or low quality.

It also does not mean the treatment is working better. Cell quality is better assessed through documented manufacturing and release testing, including sterility, mycoplasma, endotoxin, identity, viability, and other product-specific quality criteria.

The patient’s symptoms still matter. Mild, short-lived reactions and persistent or severe illness should not be treated as equivalent. When fever is high, worsening, prolonged, or accompanied by other concerning symptoms, the treating medical team should assess the patient rather than assuming the reaction is expected.

Frequently Asked Questions

• Does fever after a stem cell IV mean the cells were contaminated?

Not by itself. Temporary fever has been reported following MSC infusions even in controlled clinical studies. Contamination is assessed through manufacturing quality testing rather than diagnosed from fever alone.

• Is fever a sign that stem cells are working?

No. There is no established evidence that developing fever predicts a better clinical response. Patients who have no fever should not assume their treatment was ineffective.

• Does fever mean my body is rejecting donor UC-MSCs?

A mild temporary fever does not demonstrate rejection. UC-MSCs have relatively low immunogenicity, although interaction between donor cells and the immune system remains an active area of research.

• When should fever after treatment be checked by a doctor?

Patients should contact their medical team if fever is high, persistent, worsening, or accompanied by symptoms such as severe chills, breathing difficulty, chest discomfort, confusion, rash, significant weakness, or other concerning changes.

• Can poor-quality stem cells cause fever?

Manufacturing problems such as microbial or endotoxin contamination could potentially cause inflammatory symptoms, including fever. However, fever alone cannot identify the cause, which is why appropriate quality testing and clinical assessment are both important.

Related Reading

• Is It Normal to Have a Fever After Stem Cell Therapy?
• Do Stem Cells Need to Match Blood Type?
• What Are the Benefits and Limitations of Umbilical Cord Mesenchymal Stem Cells?

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
Website: www.ednawellness.com

References

• Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine. 2020. https://pubmed.ncbi.nlm.nih.gov/31989101/
• Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. 2026. https://pubmed.ncbi.nlm.nih.gov/42246109/
• Wang Y, Yi H, Song Y. Transient Fever: The Sole Treatment-Related Adverse Event Associated with Mesenchymal Stromal Cells and Solid Clues from the Real World. 2023. https://pubmed.ncbi.nlm.nih.gov/37909436/
• Sanz-Nogués C, O’Brien T. Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents. Biomaterials and Biosystems. 2021. https://pubmed.ncbi.nlm.nih.gov/36824657/
• U.S. Food and Drug Administration. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy